Skip to main content

LLS News Network

LLS News Network

LLS Statement on COVID-19 Omicron Variant for Blood Cancer Patients and Survivors

Rye Brook, N.Y., January 4, 2022 – Given the rapid rise in COVID-19 infections caused by the Omicron variant, The Leukemia & Lymphoma Society has developed this page to provide blood cancer patients and survivors with the latest information about this rapidly emerging situation.

Read More

FDA Approves First Drug for The Prevention of Acute Graft Versus Host Disease

Rye Brook, N.Y., December 15, 2021 – The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of acute graft versus host disease (aGVHD) in patients 2 years and older who underwent a stem cell transplant from an unrelated donor

Read More

Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 Vaccine

Study supports the Centers for Disease Control and Prevention (CDC) recommendation for immunocompromised adults  

Read More

FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse

Rye Brook, N.Y., December 1, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectable antibody is approved alone or in combination with other drugs at different states of multiple myeloma treatment.

Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.